Dr Delphine Larrieu completed her Master's degree in Integrative and Cell Biology at the University of California, Irvine (UCI) and at the University of Grenoble, France. She then carried out her PhD at the Institute for Advanced Biosciences in Grenoble, working on tumour suppressor genes and their involvement in DNA replication and repair. In 2011, she moved to the University of Cambridge for her postdoctoral research in the Steve Jackson Laboratory, with personal funding from EMBO and from the Medical Research Council (MRC). During her time as a postdoc, Delphine developed a strong interest in understanding nuclear envelope function and its links with disease, more specifically premature ageing. In 2017, Delphine was awarded a Wellcome Trust Sir Henry Dale fellowship, to set up her own lab at the Cambridge Institute for Medical Research to pursue her research in the field of nuclear envelope. In 2022, she was appointed as an Assistant Professor at the Department of Pharmacology, University of Cambridge.
Delphine also has a strong interest in translational research. In 2020, she co-founded Adrestia Therapeutics, whose aim is to restore the biological balance in disease. She is also a scientific advisor for Shift Bioscience, whose mission is to discover new cellular rejuvenation pathways.
